Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Asset Purchase Agreements (Narrative) (Details)

Asset Purchase Agreements (Narrative) (Details) $ / shares in Units, $ in Thousands												1 Months Ended					3 Months Ended		9 Months Ended
	Nov. 15, 2023 USD ($) D	Nov. 14, 2023 USD ($)	Nov. 07, 2023 USD ($)	Jul. 28, 2023 USD ($)	Apr. 21, 2023 USD ($)	Feb. 03, 2023 USD ($)	Jan. 27, 2023 shares	Dec. 30, 2022 USD ($) shares	Oct. 11, 2022 USD ($)	Feb. 24, 2021 USD ($)	Nov. 12, 2018	Nov. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Jul. 31, 2023 USD ($)	Feb. 28, 2023 USD ($) $ / shares shares	Feb. 28, 2019 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Proceeds from Issuance of Common Stock																			$ 2,056	$ 5,750
Collaboration revenue																	$ 182	$ 364	546	1,518
Sale of stock, number of shares issued \| shares								4,900,000							1,180,000
Stock offering, price per share \| $ / shares															$ 5.25
Sale of Stock, Consideration Received on Transaction		$ 8,900						$ 150,000						$ 9,100	$ 6,700
Cyprium \| Sentnyl
Upfront fees payment										$ 8,000
Collaboration revenue																	200	$ 400	500	$ 1,500
Avenue
Proceeds from Issuance of Common Stock									$ 10,300
Sale of stock, number of shares issued \| shares							448,000
Avenue \| InvaGen
Payments of milestones						$ 200
Percentage of shares repurchased									100.00%
Purchase price of shares repurchased									$ 3,000
Percentage of contingent fee payable									7.50%
Contingent fee payable from proceeds of future financing									$ 4,000
Aevitas \| Maximum \| Asset purchase agreement to acquire Aevitas proprietary rights
Upfront payment to be paid					$ 140,000
Mustang
Expenses under manufacturing services agreement																	1,700		1,700
Asset acquisition, minimum commitment amount				$ 8,000
Manufacturing services in excess of the minimum commitment				$ 3,000
Asset acquisition, minimum commitment amount payment, term				2 years
Asset acquisition, minimum commitment amount paid, percentage				25.00%
Mustang \| Manufacturing Services Agreement [Member]
Reimbursed costs																	2,500
Mustang \| UBriGene
Consideration Transferred				$ 6,000
Contingent liability				$ 5,000
Contingent consideration period				2 years
Contingent liability, Issuance of equity securities				$ 10,000
Contingent consideration, Proposed lease period				2 years
Bookvalue of lease liability																	3,500		3,500
Loss on sale of asset																	$ 1,400		$ 1,400
Transaction Related Expenses				$ 300
SPMA \| Avenue \| InvaGen
Sale of stock, ownership percentage after the transaction											33.30%
Subsequent events
Sale of Stock, Consideration Received on Transaction												$ 8,900
Subsequent events \| Cyprium \| Sentnyl
Contingent liability	$ 4,500
Subsequent events \| Avenue
Proceeds from Issuance of Common Stock												5,000
Sale of Stock, Consideration Received on Transaction												$ 1,100
Subsequent events \| Avenue \| InvaGen
Payments of milestones			$ 300
Subsequent events \| Mustang
Sale of Stock, Consideration Received on Transaction													$ 3,900
Subsequent events \| SPMA \| Cyprium \| Sentnyl
Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained \| D	45
FDA approval of the NDA \| Cyprium \| Sentnyl \| Maximum
Payments of milestones										$ 133,500
Strategic Transaction, First Stage \| SPMA \| Avenue \| InvaGen
Sale of stock, ownership percentage after the transaction																33.30%
Sale of stock, number of shares issued \| shares																400,000
Stock offering, price per share \| $ / shares																$ 90.00
Sale of Stock, Consideration Received on Transaction																$ 35,000